Rapport Therapeutics Inc
RAPP14.040USD
-0.110-0.78%
收盘 08/04, 16:00（美东）报价延迟15分钟
512.42M总市值
亏损市盈率 TTM
关于 Rapport Therapeutics Inc 公司
Rapport Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于发现和开发一系列精准小分子候选产品。该公司专注于开发一类新型精准神经药物，旨在为患者提供现有中枢神经系统疾病治疗方法的替代方案。该公司为患有中枢神经系统 (CNS) 疾病的患者推进了一系列治疗方案，包括局灶性癫痫、疼痛、躁郁症和听力障碍。该公司的离子型谷氨酸受体 (iGluR) 是由神经递质谷氨酸激活的配体门控离子通道。该公司的 RAP-219 是一种临床阶段的小分子，旨在通过选择性靶向一种称为 TARPy8 的 RAP 来实现神经解剖学特异性，TARPy8 与神经元 AMPAR 相关，后者是临床验证的癫痫靶点。
公司简介
公司代码RAPP
公司名称Rapport Therapeutics Inc
上市日期Jun 07, 2024
CEOMr. Abraham N. (Abe) Ceesay
员工数量69
证券类型Ordinary Share
年结日Jun 07
公司地址99 High Street
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02110
电话18573218020
网址https://www.rapportrx.com/
公司代码RAPP
上市日期Jun 07, 2024
CEOMr. Abraham N. (Abe) Ceesay
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
789.71K
--
Dr. Steven M. (Steve) Paul, M.D.
Dr. Steven M. (Steve) Paul, M.D.
Chairman of the Board
Chairman of the Board
477.64K
--
Mr. David Bredt, M.D., Ph.D.
Mr. David Bredt, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
435.14K
-1.92%
Ms. Cheryl Gault
Ms. Cheryl Gault
Chief Operating Officer
Chief Operating Officer
171.93K
+8.86%
Dr. Bradley S. Galer, M.D.
Dr. Bradley S. Galer, M.D.
Chief Medical Officer
Chief Medical Officer
111.42K
-43.56%
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Chief Financial Officer
Chief Financial Officer
10.00K
--
Mr. Robert J. (Rob) Perez
Mr. Robert J. (Rob) Perez
Director
Director
--
--
Dr. James I. Healy, M.D., Ph.D.
Dr. James I. Healy, M.D., Ph.D.
Director
Director
--
--
Mr. Raymond Kelleher, M.D., Ph.D.
Mr. Raymond Kelleher, M.D., Ph.D.
Director
Director
--
--
Ms. Wendy B. Young, Ph.D.
Ms. Wendy B. Young, Ph.D.
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
789.71K
--
Dr. Steven M. (Steve) Paul, M.D.
Dr. Steven M. (Steve) Paul, M.D.
Chairman of the Board
Chairman of the Board
477.64K
--
Mr. David Bredt, M.D., Ph.D.
Mr. David Bredt, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
435.14K
-1.92%
Ms. Cheryl Gault
Ms. Cheryl Gault
Chief Operating Officer
Chief Operating Officer
171.93K
+8.86%
Dr. Bradley S. Galer, M.D.
Dr. Bradley S. Galer, M.D.
Chief Medical Officer
Chief Medical Officer
111.42K
-43.56%
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Chief Financial Officer
Chief Financial Officer
10.00K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月3日 周日
更新时间: 8月3日 周日
持股股东
股东类型
持股股东
持股股东
占比
Third Rock Ventures, LLC
22.21%
Fidelity Management & Research Company LLC
15.03%
ARCH Venture Partners
10.22%
Cormorant Asset Management, LP
8.06%
Capital International Investors
7.13%
Other
37.36%
持股股东
持股股东
占比
Third Rock Ventures, LLC
22.21%
Fidelity Management & Research Company LLC
15.03%
ARCH Venture Partners
10.22%
Cormorant Asset Management, LP
8.06%
Capital International Investors
7.13%
Other
37.36%
股东类型
持股股东
占比
Venture Capital
45.35%
Investment Advisor
39.88%
Hedge Fund
10.82%
Individual Investor
6.28%
Investment Advisor/Hedge Fund
5.26%
Research Firm
3.58%
Bank and Trust
0.19%
Sovereign Wealth Fund
0.13%
Pension Fund
0.10%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
153
43.35M
118.77%
+3.80M
2025Q1
149
47.96M
131.36%
+9.87M
2024Q4
117
46.27M
126.51%
+9.23M
2024Q3
91
39.09M
106.87%
+12.18M
2024Q2
48
37.49M
102.49%
+37.49M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Third Rock Ventures, LLC
8.10M
22.21%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.49M
15.03%
--
--
Mar 31, 2025
ARCH Venture Partners
3.73M
10.22%
--
--
Mar 31, 2025
Cormorant Asset Management, LP
2.94M
8.06%
--
--
Mar 31, 2025
Capital International Investors
2.60M
7.13%
--
--
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.50M
6.84%
--
--
Mar 31, 2025
Sofinnova Investments, Inc
2.00M
5.47%
--
--
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
1.55M
4.25%
-85.01K
-5.19%
Mar 31, 2025
Goldman Sachs & Company, Inc.
1.24M
3.41%
-7.83K
-0.63%
Mar 31, 2025
The Vanguard Group, Inc.
1.11M
3.05%
+559.95K
+101.51%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.92%
iShares Neuroscience and Healthcare ETF
0.49%
ALPS Medical Breakthroughs ETF
0.28%
Tema Neuroscience and Mental Health ETF
0.13%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
iShares Micro-Cap ETF
0.04%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Value ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.92%
iShares Neuroscience and Healthcare ETF
占比0.49%
ALPS Medical Breakthroughs ETF
占比0.28%
Tema Neuroscience and Mental Health ETF
占比0.13%
Invesco Nasdaq Biotechnology ETF
占比0.05%
ProShares Ultra Nasdaq Biotechnology
占比0.05%
iShares Micro-Cap ETF
占比0.04%
iShares Biotechnology ETF
占比0.02%
ProShares UltraPro Russell2000
占比0.01%
iShares Russell 2000 Value ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
